Development of anti-HIV peptides based on a viral capsid protein

被引:12
作者
Mizuguchi, Takaaki [1 ]
Ohashi, Nami [1 ]
Matsumoto, Daichi [1 ]
Hashimoto, Chie [1 ]
Nomura, Wataru [1 ]
Yamamoto, Naoki [2 ]
Murakami, Tsutomu [3 ]
Tamamura, Hirokazu [1 ]
机构
[1] Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Chiyoda Ku, Tokyo 1010062, Japan
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117597, Singapore
[3] Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, Tokyo 1628640, Japan
关键词
anti-HIV; capsid protein; chloroquine; octa-arginyl group; overlapping peptide; HUMAN-IMMUNODEFICIENCY-VIRUS; GENE-PRODUCTS; CD4; MIMICS; INTEGRASE INHIBITORS; ENTRY INHIBITORS; MATRIX PROTEIN; LIFE-CYCLE; TYPE-1; POTENT; CXCR4;
D O I
10.1002/bip.22920
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Peptide inhibitors with cell permeability targeting an HIV-1 capsid (CA) protein might make therapeutic by regulating HIV-1 replication. Overlapping fragment peptide libraries covering the whole sequence of an HIV-1 CA protein have been synthesized with the addition of an octa-arginyl moiety to increase their cell permeability. Amongst these peptides, several compounds which inhibit the HIV-1 replication cycle have been found. Conjugation of cell-penetrating functions such as an octa-arginyl group to individual peptides in combination with the addition of chloroquine in cell-based anti-HIV assays was previously proven to be a useful assay method with which to search for active peptides. Anti-HIV assays have been performed in the presence or absence of chloroquine and found that most of compounds have higher anti-HIV activity in the presence, rather than in the absence of chloroquine. Some potent seeds as anti-HIV agents might naturally lie hidden in CA proteins, and could become useful leads to HIV inhibitors.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Protein recognition of macrocycles: Binding of anti-HIV metallocyclams to lysozyme
    Hunter, TM
    McNae, IW
    Liang, XY
    Bella, J
    Parsons, S
    Walkinshaw, MD
    Sadler, PJ
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (07) : 2288 - 2292
  • [22] NMR structures of anti-HIV D-peptides derived from the N-terminus of viral chemokine vMIP-II
    Mori, M
    Liu, DX
    Kumar, S
    Huang, ZW
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 335 (03) : 651 - 658
  • [23] Virus entry as a target for anti-HIV intervention
    Esté, JA
    CURRENT MEDICINAL CHEMISTRY, 2003, 10 (17) : 1617 - 1632
  • [24] Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies
    Ahmed, Yousuf
    Tian, Meijuan
    Gao, Yong
    AIDS RESEARCH AND THERAPY, 2017, 14
  • [25] Current Computational Approaches for the Development of Anti-HIV Inhibitors: An Overview
    Panwar, Umesh
    Chandra, Ishwar
    Selvaraj, Chandrabose
    Singh, Sanjeev K.
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (31) : 3390 - 3405
  • [26] Recent advances on anti-HIV vaginal delivery systems development
    Antimisiaris, Sophia G.
    Mourtas, Spyridon
    ADVANCED DRUG DELIVERY REVIEWS, 2015, 92 : 123 - 145
  • [27] Engineering strategies of Anti-HIV antibody therapeutics in clinical development
    Pihlstrom, Nicole
    Bournazos, Stylianos
    CURRENT OPINION IN HIV AND AIDS, 2023, 18 (04) : 184 - 190
  • [28] Pyrazole Containing Anti-HIV Agents: An Update
    Kumar, Sanjay
    Gupta, Shiv
    Rani, Varsha
    Sharma, Priyanka
    MEDICINAL CHEMISTRY, 2022, 18 (08) : 831 - 846
  • [29] Designed Multiple Ligands: An Emerging Anti-HIV Drug Discovery Paradigm
    Zhan, Peng
    Liu, Xinyong
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (16) : 1893 - 1917
  • [30] Recent Advances in the Discovery and Development of Anti-HIV Natural Products
    Ma, Xinyu
    Zhang, Hongjia
    Wang, Shirui
    Deng, Rui
    Luo, Dan
    Luo, Meng
    Huang, Qing
    Yu, Su
    Pu, Chunlan
    Liu, Yuanyuan
    Tong, Yu
    Li, Rui
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2022, 50 (05): : 1173 - 1196